Australia markets open in 1 hour 30 minutes
  • ALL ORDS

    6,796.90
    +76.50 (+1.14%)
     
  • AUD/USD

    0.6871
    +0.0053 (+0.78%)
     
  • ASX 200

    6,612.60
    +72.70 (+1.11%)
     
  • OIL

    110.49
    +2.06 (+1.90%)
     
  • GOLD

    1,809.10
    +7.60 (+0.42%)
     
  • BTC-AUD

    29,027.87
    +715.17 (+2.53%)
     
  • CMC Crypto 200

    429.24
    +9.10 (+2.17%)
     

Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

EVANSTON, Ill., May 17, 2022--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.

The poster highlights data from preclinical studies showing that NYX-783, an NMDA receptor positive allosteric modulator, builds long-lasting fear-inhibitory memories in PTSD-relevant models, ultimately leading to reduced spontaneous recovery (i.e., return) of fear. NYX-783 is currently being evaluated in a Phase 2b study in patients with PTSD.

Poster presentations details:

Date/Time: Tuesday, May 24, 2022 at 12:00 PM–1:00 PM CT

Poster Title: NYX-783, a Novel Positive Allosteric Modulator of the N-Methyl D-Aspartate Receptor, Facilitates Extinction Learning in PTSD-Relevant Mouse Models

Session: Poster Session 7

Poster Number: P7-094

Room: Hall G, First Floor, Ernest N. Morial Convention Center

Poster Presenter: Katie Leaderbrand, Ph.D.

Following the presentation, the poster will be available to view on the "Publications" page in the "Pipeline" section of Aptinyx’s website.

About Post-Traumatic Stress Disorder

Approximately fifteen million adults in the United States suffer from PTSD in a given year, which is characterized by intrusive symptoms, avoidance, negative alteration in cognition and mood, hyperarousal, and/or arousal alterations following the experience of trauma. PTSD can result from various forms of trauma, including combat exposure, car accidents, sexual or other physical assault, abuse, natural disasters, and others. The lifetime prevalence of PTSD is approximately seven percent in the general population but is much higher in populations at risk for exposure to trauma, such as military service members and first responders. In addition to the challenges associated with the direct symptoms, PTSD sufferers have a higher rate of suicide and often struggle with simultaneous addiction, leading to an even greater social and economic burden of the disorder. Available therapeutic options are limited in treating PTSD, including only two approved conventional SSRI antidepressants, which have limited efficacy, undesirable side effects, and target only the symptoms of PTSD, not the underlying disorder itself.

About NYX-783

NYX-783 is a novel, oral, positive allosteric modulator of NMDA receptors currently in Phase 2b development for the treatment of post-traumatic stress disorder (PTSD). In preclinical studies of NYX-783, particularly strong results were observed in psychiatric models, models of fear extinction, and models of substance abuse. In a Phase 1 clinical study of NYX-783, ample central nervous system exposure was observed and the product candidate demonstrated a favorable adverse event and tolerability profile, with no serious adverse effects, across a wide dose range. In an exploratory Phase 2a study in patients with PTSD, patients receiving a 50 mg dose level of NYX-783 showed meaningful symptom improvements and rates of response. The U.S. Food and Drug Administration has granted Fast Track designation to the development of NYX-783 for the treatment of PTSD.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the therapeutic effects of NYX-783 and expectations regarding the design, implementation, timing, and success of the company’s planned clinical trials. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company’s product candidate development activities and planned clinical studies; the company’s ability to execute on its strategy; regulatory developments in the United States and foreign countries; as well as those risks and uncertainties set forth in the company’s most recent annual report on Form 10-K and in its other filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005553/en/

Contacts

Investor Contacts:
Patrick Flavin
Aptinyx Inc.
ir@aptinyx.com
847-871-0377

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting